AR037931A1 - Metodo para granulacion humeda de azitromicina - Google Patents

Metodo para granulacion humeda de azitromicina

Info

Publication number
AR037931A1
AR037931A1 ARP020105017A ARP020105017A AR037931A1 AR 037931 A1 AR037931 A1 AR 037931A1 AR P020105017 A ARP020105017 A AR P020105017A AR P020105017 A ARP020105017 A AR P020105017A AR 037931 A1 AR037931 A1 AR 037931A1
Authority
AR
Argentina
Prior art keywords
dihydrate
granules
azithromycin
azitromycin
wet granulation
Prior art date
Application number
ARP020105017A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR037931A1 publication Critical patent/AR037931A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Método de formación de gránulos de azitromicina no dihidrato, que comprende mezclar partículas de azitromicina no dihidrato, con una cantidad de granulación de un líquido de granulación, y, opcionalmente, con partículas de uno o más excipientes, para formar gránulos húmedos que comprenden azitromicina no dihidrato y el líquido de granulación. Los gránulos se secan después para separar el líquido de granulación. Composición farmacéutica que comprende gránuilos de una azitromicina no dihidrato y al menos un excipiente farmacéuticamente aceptable. Formulaciones farmacéticas que comprenden gránulos de azitromicina no dihidrato. Gránulos de azitormicina dihidrato que comprenden 98% o más de azitromicina dihidrata y desde aproximadamente 2% a 0% en peso total, de uno o más excipientes farmacéuticamente aceptables.
ARP020105017A 2001-12-21 2002-12-19 Metodo para granulacion humeda de azitromicina AR037931A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34346901P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
AR037931A1 true AR037931A1 (es) 2004-12-22

Family

ID=23346249

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020105017A AR037931A1 (es) 2001-12-21 2002-12-19 Metodo para granulacion humeda de azitromicina

Country Status (21)

Country Link
US (1) US20030190365A1 (es)
EP (1) EP1455757A2 (es)
JP (1) JP2005515212A (es)
KR (1) KR100669279B1 (es)
CN (1) CN1606433A (es)
AR (1) AR037931A1 (es)
AU (1) AU2002353316A1 (es)
BR (1) BR0215175A (es)
CA (1) CA2470055A1 (es)
HN (1) HN2002000376A (es)
IL (1) IL161259A0 (es)
MX (1) MXPA04003027A (es)
NO (1) NO20042575L (es)
NZ (1) NZ532063A (es)
PA (1) PA8562101A1 (es)
PE (1) PE20030588A1 (es)
PL (1) PL371125A1 (es)
RU (1) RU2283651C2 (es)
TW (1) TW200301260A (es)
WO (1) WO2003053399A2 (es)
ZA (1) ZA200402586B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
WO2003053416A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
EP1648472A2 (en) * 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Stable oral compositions of azithromycin monohydrate
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
DE602004014805D1 (de) 2003-12-04 2008-08-14 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
NZ547806A (en) * 2003-12-23 2009-11-27 Temrel Ltd Process for producing pellets for pharmaceutical compositions
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
CN100441196C (zh) * 2006-12-15 2008-12-10 北京化工大学 一种制备微粉化阿奇霉素的方法
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
SG171362A1 (en) * 2008-11-20 2011-07-28 Avantor Performance Mat Inc Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP2295037A1 (en) * 2009-09-11 2011-03-16 Ratiopharm GmbH Pharmaceutical formulation containing Ribavirin
RU2480689C1 (ru) * 2011-10-26 2013-04-27 Александр Михайлович Муртищев Способ получения порошкообразных продуктов
WO2017129088A1 (zh) * 2016-01-27 2017-08-03 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物的制备方法
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
CN110292567B (zh) * 2019-05-17 2022-02-18 北京悦康科创医药科技股份有限公司 一种阿奇霉素胶囊的制备方法
CN113088422A (zh) * 2021-05-18 2021-07-09 耿艳飞 一种荞麦果醋
CN113559073A (zh) * 2021-07-20 2021-10-29 海南海神同洲制药有限公司 阿奇霉素片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) * 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
DE19706978A1 (de) * 1997-02-21 1998-08-27 Ulrich Dr Posanski Kombinationspräparat für oral applizierbare Antibiotika
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
RU2240124C2 (ru) * 1998-11-30 2004-11-20 Тева Фармасьютикал Индастриз, Лтд. Этанолят азитромицина, процесс получения и содержащие его фармацевтические составы
ES2267549T3 (es) * 1999-06-29 2007-03-16 Sandoz Ag Procedimiento para la produccion de azitromicina.
NZ539801A (en) * 2001-05-22 2006-10-27 Pfizer Prod Inc Crystal forms of azithromycin
PT1446010E (pt) * 2001-10-18 2009-06-08 Teva Pharma Composições de azitromicina estabilizadas

Also Published As

Publication number Publication date
HN2002000376A (es) 2003-02-21
RU2004118502A (ru) 2005-04-10
MXPA04003027A (es) 2004-07-05
BR0215175A (pt) 2004-12-28
RU2283651C2 (ru) 2006-09-20
EP1455757A2 (en) 2004-09-15
PA8562101A1 (es) 2005-02-04
PL371125A1 (en) 2005-06-13
WO2003053399A2 (en) 2003-07-03
KR100669279B1 (ko) 2007-01-16
US20030190365A1 (en) 2003-10-09
CN1606433A (zh) 2005-04-13
TW200301260A (en) 2003-07-01
KR20040073504A (ko) 2004-08-19
PE20030588A1 (es) 2003-07-08
JP2005515212A (ja) 2005-05-26
NZ532063A (en) 2006-03-31
CA2470055A1 (en) 2003-07-03
AU2002353316A1 (en) 2003-07-09
NO20042575L (no) 2004-06-18
ZA200402586B (en) 2005-04-01
WO2003053399A3 (en) 2004-05-21
IL161259A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
AR037931A1 (es) Metodo para granulacion humeda de azitromicina
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
CO5611118A2 (es) Formulaciones de azitromicina granuladas por via seca
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
AR041370A1 (es) Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
IT1282352B1 (it) Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per
DE60104399D1 (de) Pulverformulierung zur inhalation
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
BR0207871A (pt) Composição para liberar bisfosfonato para um alvo
AR063555A1 (es) Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos
CO5590918A2 (es) Formulaciones
CO5280222A1 (es) Composicion farmaceutica que comprende pemetrexed
AR011919A1 (es) FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA
ATE366105T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
AR038143A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
RS51677B (en) PHARMACEUTICAL COMPOSITION COVERING AMLODIPINE BEZILATE AND LISINOPRIL DIHYDRATE AND PROCEDURE FOR THEIR PREPARATION
AR018347A1 (es) 1h-indazoles 1,5 y 3-o-sustituidos y sus sales fisiologicamente tolerables, utilizacion de los mismos para la preparacion de medicamentos, procedimientospara preparar dichos compuestos, las composiciones y preparaciones farmaceuticas que los contienen, y la utilizacion de dichos compuestos y prepara
AR044869A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
UY27399A1 (es) Proceso para la preparación de quinazolinas
ATE371644T1 (de) Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
FB Suspension of granting procedure